CCNT1
CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
Overview
Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II). Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II. Serves as an essential cofactor for Tat, by promoting RNA Pol II activation, allowing transcription of viral genes.
IntOGen calls it a driver in 1 cohort (0 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
- 1 · What it is
CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
- 2 · What goes wrong in cancer
Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II).
- 3 · How drugs use it
No product in this corpus aims at CCNT1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:1599 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O60563 (protein name, function text, keywords and locations (REST API)); IntOGen CCNT1 (driver in 1 cohort (Act 0, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II). Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II. Serves as an essential cofactor for Tat, by promoting RNA Pol II activation, allowing transcription of viral genes. Location: Nucleus (UniProt). Locus 12q13.11-q13.12 (HGNC).
- Acute myeloid leukaemia: IntOGen driver in 1 cohort (AML)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: none stated by the sources. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CCNT1" OR ABSTRACT:"CCNT1" OR TITLE:"cyclin T1" OR ABSTRACT:"cyclin T1" OR TITLE:"Cyclin-T1" OR ABSTRACT:"Cyclin-T1" OR TITLE:"CYCT1" OR ABSTRACT:"CYCT1" OR TITLE:"HIVE1" OR ABSTRACT:"HIVE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCNT1, not a curated reading list.